Pulmonx (NASDAQ:LUNG) executives said the company is entering 2026 focused on rebuilding U.S. momentum, advancing clinical programs designed to expand its total addressable market, and tightening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results